natgillin/translations-raw huggingface dataset:
* Frequency for adverse reactions detected by spontaneous reports is described as “not known”
motnje pri spolnosti, spremembe libida * Pogostnost neželenih učinkov, o katerih so bila prejeta spontana poročila, je označena kot “Neznana”.
Since Irbesartan Hydrochlorothiazide BMS contains hydrochlorothiazide, it is not recommended during the first trimester of pregnancy.
Zdravilo Irbesartan Hydrochlorothiazide BMS vsebuje hidroklorotiazid, zato njegova uporaba v prvem trimesečju nosečnosti ni priporočena.
Renal impairment and kidney transplantation: when Irbesartan Hydrochlorothiazide BMS is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
Ledvična okvara in presaditev ledvic: če se zdravilo Irbesartan Hydrochlorothiazide BMS uporablja pri bolnikih z okvarjeno ledvično funkcijo, je priporočena redna kontrola serumske koncentracije kalija, kreatinina in sečne kisline.
Such conditions should be corrected before initiating therapy with Irbesartan Hydrochlorothiazide BMS.
Ta stanja je treba popraviti pred začetkom zdravljenja z zdravilom Irbesartan Hydrochlorothiazide BMS.
Digitalis glycosides: thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias (see section 4.4);
Digitalisovi glikozidi: tiazidi, ki povzročajo hipokaliemijo ali hipomagneziemijo, lahko sprožijo z digitalisom inducirano srčno aritmijo (glejte poglavje 4.4).
General: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotemia, oliguria, or rarely acute renal failure.
Splošno: pri bolnikih, pri katerih sta tonus žilja in delovanje ledvic odvisna predvsem od delovanja sistema renin-angiotenzin-aldosteron (na primer pri bolnikih s hudo kongestivno srčno insuficienco ali ledvično boleznijo, vključno s stenozo ledvične arterije), se lahko med zdravljenjem z zaviralci angiotenzinske konvertaze ali antagonisti angiotenzina II, ki vplivajo na ta sistem, pojavijo akutna hipotenzija, azotemija, oligurija ali redko akutna ledvična odpoved.
Irbesartan Hydrochlorothiazide BMS should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
Zdravilo Irbesartan Hydrochlorothiazide BMS se pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) ne sme uporabljati (glejte poglavje 4.3).
anaphylactic reactions, toxic epidermal necrolysis, necrotizing angitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria
anafilaktične reakcije, toksična epidermalna nekroliza, nekrotizirajoči angiitis (vaskulitis, vnetje kožnih žil ali mezgovnic), reakcije, podobne kožnemu eritematoznemu lupusu, fotosenzitivne reakcije, izpuščaj, urtikarija
No dosage adjustment is necessary in elderly patients.
Starejšim bolnikom odmerka ni treba prilagoditi.
Your doctor will normally advise you to stop taking Irbesartan Hydrochlorothiazide BMS before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Irbesartan Hydrochlorothiazide BMS.
Zdravnik vam bo praviloma svetoval, da zdravljenje z zdravilom Irbesartan Hydrochlorothiazide BMS prekinete še preden zanosite ali takoj, ko se izkaže, da ste zanosili in vam predpisal zdravljenje z drugim zdravilom.
Tables 2 and 3 below detail the adverse reactions reported with the individual components of Irbesartan Hydrochlorothiazide BMS.
V tabeli 2 in 3 so navedeni neželeni učinki, o katerih so poročali pri uporabi posamezne zdravilne učinkovine zdravila Irbesartan Hydrochlorothiazide BMS.
Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalaemia, hyponatraemia, and hypochloremic alkalosis).
Tiazidni diuretiki, vključno s hidroklorotiazidom, lahko porušijo ravnovesje tekočin ali elektrolitov (hipokaliemija, hiponatriemija, hipokloriemična alkaloza).
Important information about some of the ingredients of Irbesartan Hydrochlorothiazide BMS Irbesartan Hydrochlorothiazide BMS contains lactose.
Pomembne informacije o nekaterih sestavinah zdravila Irbesartan Hydrochlorothiazide BMS Zdravilo Irbesartan Hydrochlorothiazide BMS vsebuje laktozo.
The usual dose of Irbesartan Hydrochlorothiazide BMS is one or two tablets a day.
Običajni odmerek zdravila Irbesartan Hydrochlorothiazide BMS je ena ali dve tableti na dan.
Conversely, based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin sodium) may lead to increases in serum potassium.
Na podlagi izkušenj z drugimi zdravili, ki zavirajo sistem renin-angiotenzin-aldosteron, domnevamo, da se lahko pri sočasni uporabi antikaliuretičnih diuretikov, pripravkov s kalijem, nadomestkov soli, ki vsebujejo kalij, ali drugih zdravil, ki zvečujejo serumske koncentracije kalija (na primer natrijev heparinat), serumska koncentracija kalija zviša.
Based on its pharmacodynamic properties, Irbesartan Hydrochlorothiazide BMS is unlikely to affect this ability.
Na osnovi farmakodinamičnih lastnosti je malo verjetno, da bi zdravilo Irbesartan Hydrochlorothiazide BMS vplivalo na te sposobnosti.
These undesirable effects are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat.
Ti neželeni učinki so: glavobol, zvonjenje v ušesih, kašelj, motnje okušanja, prebavne motnje, bolečine v sklepih in mišicah, nenormalno delovanje jeter, okvara delovanja ledvic, zvišanje vrednosti kalija v krvi in alergijske reakcije, kot so izpuščaj, koprivnica in lokalizirana oteklina obraza, ustnic, ust, jezika ali žrela.
After either oral or intravenous administration of 14C irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces.
Po peroralni ali intravenski uporabi irbesartana 14C se s sečem izloči približno 20% radioaktivne snovi, preostanek pa z blatom.
14 tablets 28 tablets 56 tablets 56 x 1 tablets 84 tablets 98 tablets
14 tablet 28 tablet 56 tablet 56 x 1 tableta 84 tablet 98 tablet
The following changes, observed in rats and macaques receiving the irbesartan/hydrochlorothiazide combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were observed): kidney changes, characterized by slight increases in serum urea and creatinine, and hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the interaction of irbesartan with the renin-angiotensin system; slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit); stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day.
Pri podganah in opicah, ki so prejemale kombinacijo 10 mg irbesartana in 10 mg hidroklorotiazida na kg/dan ter 90 mg irbesartana in 90 mg hidroklorotiazida na kg/dan, so se po znižanju krvnega tlaka (pri čemer niso opazili pomembnih toksikoloških interakcij) zaradi uporabe ene učinkovine ali kombiniranega dajanja pojavile naslednje spremembe: ledvične spremembe so se kazale kot blago zvečanje sečnine in kreatinina v serumu ter hiperplazija/hipertrofija jukstaglomerulnega aparata, kar je neposredna posledica interakcije med irbesartanom in sistemom renin-angiotenzin blago zmanjšanje eritrocitnih parametrov (eritrocitov, hemoglobina in hematokrita) pri nekaj podganah, ki so v študiji toksičnosti 6 mesecev dobivale po 90 mg irbesartana na kg/dan in 90 mg hidroklorotiazida na kg/dan ter kombinacijo irbesartana in hidroklorotiazida (10 mg/10 mg/kg/dan), so opazili spremembo barve želodca, razjede in fokalno nekrozo želodčne sluznice; teh lezij pri opicah ni bilo znižanje kalija v serumu med uporabo hidroklorotiazida, ki je bilo med kombiniranim dajanjem z irbesartanom manj izrazito.
Common side effects (affect 1 to 10 users in 100) nausea/vomiting abnormal urination fatigue dizziness (including when getting up from a lying or sitting position) blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).
Pogosti neželeni učinki (pojavijo se pri 1 do 10 od 100 bolnikov) siljenje na bruhanje/bruhanje nenormalno uriniranje utrujenost omotica (tudi pri vstajanju iz ležečega ali sedečega položaja) krvne preiskave lahko pokažejo zvišanje vrednosti encima, ki kaže na delovanje mišic in srca (encim kreatin-kinaza), ali zvišanje vrednosti snovi, ki so merilo delovanja ledvic (dušik sečnine v krvi, kreatinin).
Taking Irbesartan Hydrochlorothiazide BMS with food and drink Irbesartan Hydrochlorothiazide BMS can be taken with or without food.
Jemanje zdravila Irbesartan Hydrochlorothiazide BMS skupaj s hrano in pijačo Zdravilo Irbesartan Hydrochlorothiazide BMS lahko jemljete skupaj s hrano ali brez nje.
Lithium: the combination of lithium and Irbesartan Hydrochlorothiazide BMS is not recommended (see section 4.5).
Litij: kombinacija litija in zdravila Irbesartan Hydrochlorothiazide BMS ni priporočena (glejte poglavje 4.5).
Like all medicines, Irbesartan Hydrochlorothiazide BMS can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Irbesartan Hydrochlorothiazide BMS neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Following oral administration of Irbesartan Hydrochlorothiazide BMS, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively.
Po peroralnem jemanju zdravila Irbesartan Hydrochlorothiazide BMS je biološka uporabnost irbesartana približno 60-80%, hidroklorotiazida pa 50-80%.
The usual dose of Irbesartan Hydrochlorothiazide BMS is one tablet a day.
Običajni odmerek zdravila Irbesartan Hydrochlorothiazide BMS je ena tableta na dan.
Irbesartan Hydrochlorothiazide BMS is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Zdravila Irbesartan Hydrochlorothiazide BMS ne smete jemati, če ste noseči dlje kot 3 mesece, saj lahko zdravilo v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti).
Severe hepatic impairment, biliary cirrhosis and cholestasis
Huda jetrna okvara, biliarna ciroza ali holestaza.
Other antihypertensive agents: the antihypertensive effect of Irbesartan Hydrochlorothiazide BMS may be increased with the concomitant use of other antihypertensive agents.
Drugi antihipertenzivi: antihipertenzijski učinek zdravila Irbesartan Hydrochlorothiazide BMS se lahko med sočasno uporabo drugih antihipertenzivov zveča.
Diuretic agents such as the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide BMS may have an effect on other medicines.
Diuretiki, med katere spada tudi hidroklorotiazid, ki ga vsebuje zdravilo Irbesartan Hydrochlorothiazide BMS, lahko vplivajo na delovanje drugih zdravil.
Irbesartan Hydrochlorothiazide BMS is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Zdravila Irbesartan Hydrochlorothiazide BMS ne smete jemati, če ste noseči dlje kot 3 mesece, saj lahko zdravilo po tretjem mesecu nosečnosti resno škoduje vašemu otroku.
Do not use Irbesartan Hydrochlorothiazide BMS after the expiry date which is stated on the carton and on the blister after EXP.
Zdravila Irbesartan Hydrochlorothiazide BMS ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu poleg oznake “Uporabno do”.
Therefore, the use of Irbesartan Hydrochlorothiazide BMS is not recommended.
Uporaba zdravila Irbesartan Hydrochlorothiazide BMS pri njih zato ni priporočena.
Irbesartan Hydrochlorothiazide BMS is used to treat high blood pressure, when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure.
Zdravilo Irbesartan Hydrochlorothiazide BMS uporabljamo za zdravljenje zvišanega krvnega tlaka, če pri zdravljenju samo z irbesartanom ali samo s hidroklorotiazidom krvni tlak ni bil zadostno nadzorovan.
There is no difference in response to Irbesartan Hydrochlorothiazide BMS, regardless of age or gender.
Odziv na zdravljenje z zdravilom Irbesartan Hydrochlorothiazide BMS ni odvisen od starosti ali spola.
Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Ledvična okvara: pri bolnikih z ledvično okvaro in pri tistih na hemodializi farmakokinetični parametri irbesartana niso bistveno spremenjeni.
Red and yellow ferric oxides Carnauba wax
Rdeči in rumeni železov oksid karnauba vosek
Children should not take Irbesartan Hydrochlorothiazide BMS Irbesartan Hydrochlorothiazide BMS should not be given to children under 18 years of age.
Otroci ne smejo jemati zdravila Irbesartan Hydrochlorothiazide BMS Otroci in mladostniki, mlajši od 18 let, zdravila Irbesartan Hydrochlorothiazide BMS ne smejo jemati.
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Irbesartan Hydrochlorothiazide BMS.
Dodatni podatki o posameznih učinkovinah: poleg zgoraj naštetih neželenih učinkov, ki se lahko pojavijo med uporabo kombiniranega zdravila, se utegnejo med jemanjem zdravila Irbesartan Hydrochlorothiazide BMS pojaviti tudi neželeni učinki, o katerih so predhodno poročali pri jemanju posamezne zdravilne učinkovine.
Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with Irbesartan Hydrochlorothiazide BMS.
Tiazidi zmanjšujejo ledvični očistek litija, zato se med zdravljenjem z zdravilom Irbesartan Hydrochlorothiazide BMS poveča nevarnost zastrupitve z litijem.
Due to the hydrochlorothiazide contained in Irbesartan Hydrochlorothiazide BMS, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.
Če med zdravljenjem z zdravilom Irbesartan Hydrochlorothiazide BMS uživate alkoholne pijače, lahko hidroklorotiazid, ki ga vsebuje zdravilo Irbesartan Hydrochlorothiazide BMS, povzroči omotico v stoječem položaju, še posebej po vstajanju iz sedečega položaja.
hepatitis, abnormal liver function
hepatitis, motnje delovanja jeter
Irbesartan Hydrochlorothiazide BMS is a combination of two active substances, irbesartan and hydrochlorothiazide.
Zdravilo Irbesartan Hydrochlorothiazide BMS je kombinacija dveh zdravilnih učinkovin, irbesartana in hidroklorotiazida.
Irbesartan Hydrochlorothiazide BMS is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
Zdravilo Irbesartan Hydrochlorothiazide BMS je kombinacija irbesartana, antagonista angiotenzina II, in tiazidnega diuretika hidroklorotiazida.
Colestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins;
Holestiramin in holestipol: absorpcija hidroklorotiazida je zaradi anionskih izmenjevalnih smol motena.
Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be co-administered cautiously with Irbesartan Hydrochlorothiazide BMS (see section 4.5).
Pri hkratnem zdravljenju z diuretiki, ki varčujejo kalij, pripravki s kalijem, nadomestki soli, ki vsebujejo kalij, in zdravilom Irbesartan Hydrochlorothiazide BMS je potrebna posebna previdnost (glejte poglavje 4.5).
WHAT IRBESARTAN HYDROCHLOROTHIAZIDE BMS IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO IRBESARTAN HYDROCHLOROTHIAZIDE BMS IN ZA KAJ GA UPORABLJAMO
Irbesartan Hydrochlorothiazide BMS can be taken once daily, with or without food.
Bolniki lahko zdravilo Irbesartan Hydrochlorothiazide BMS jemljejo enkrat na dan skupaj s hrano ali brez nje.
Red and black ferric oxides Carnauba wax
Rdeči in črni železov oksid karnauba vosek
Hypotension - Volume-depleted patients: Irbesartan Hydrochlorothiazide BMS has been rarely associated with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.
Hipotenzija - zmanjšan intravaskularni volumen: simptomatska hipotenzija se pri bolnikih z zvišanim krvnim tlakom, ki jemljejo zdravilo Irbesartan Hydrochlorothiazide BMS, nimajo pa drugih dejavnikov tveganja za hipotenzijo, pojavi le redko.
HOW TO TAKE IRBESARTAN HYDROCHLOROTHIAZIDE BMS
KAKO JEMATI ZDRAVILO IRBESARTAN HYDROCHLOROTHIAZIDE BMS
How to store Irbesartan Hydrochlorothiazide BMS Further information
Shranjevanje zdravila Irbesartan Hydrochlorothiazide BMS Dodatne informacije
Renal impairment: due to the hydrochlorothiazide component, Irbesartan Hydrochlorothiazide BMS is not recommended for patients with severe renal dysfunction (creatinine clearance < 30 ml/min).
Ledvična okvara: zdravilo Irbesartan Hydrochlorothiazide BMS vsebuje hidroklorotiazid, zato za bolnike s hudo motenim ledvičnim delovanjem (očistek kreatinina < 30 ml/min) ni primeren.
When necessary, Irbesartan Hydrochlorothiazide BMS may be administered with another antihypertensive medicinal product (see section 4.5).
Kadar je nujno, smejo bolniki poleg zdravila Irbesartan Hydrochlorothiazide BMS jemati tudi drug antihipertenziv (glejte poglavje 4.5).
You can take Irbesartan Hydrochlorothiazide BMS with or without food.
Zdravilo Irbesartan Hydrochlorothiazide BMS lahko jemljete s hrano ali brez nje.
Therefore, the combination of lithium and Irbesartan Hydrochlorothiazide BMS is not recommended (see section 4.4).
Sočasna uporaba litija in zdravila Irbesartan Hydrochlorothiazide BMS zato ni priporočljiva (glejte poglavje 4.4).
Marketing Authorisation Holder BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road
Imetnik dovoljenja za promet z zdravilom BRISTOL-MYERS SQUIBB PHARMA EEIG Uxbridge Business Park Sanderson Road
Irbesartan Hydrochlorothiazide BMS will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough.
Zdravnik vam je zdravilo Irbesartan Hydrochlorothiazide BMS predpisal zato, ker se med dosedanjim zdravljenjem vaš krvni tlak ni dovolj znižal.
if you get excessive vomiting or diarrhoea if you suffer from kidney problems or have a kidney transplant if you suffer from heart problems if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).
Bodite posebno pozorni pri jemanju zdravila Irbesartan Hydrochlorothiazide BMS Obvestite svojega zdravnika, če se karkoli od naslednjega nanaša na vas: če začnete prekomerno bruhati ali dobite hudo drisko če imate težave z ledvicami ali presajeno ledvico če imate težave s srcem če imate težave z jetri če imate sladkorno bolezen če imate eritematozni lupus (znan tudi kot lupus ali sistemski eritematozni lupus) če imate primarni aldosteronizem (stanje, povezano s čezmernim izločanjem hormona aldosterona, kar povzroči zastajanje natrija in posledično zvišanje krvnega tlaka)
Renal artery stenosis - Renovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists.
Stenoza ledvične arterije - renovaskularna hipertenzija: pri bolnikih z obojestransko zožitvijo ledvičnih arterij ali zožitvijo arterije delujoče ledvice se med jemanjem zaviralcev angiotenzinske konvertaze ali antagonistov angiotenzina II zveča nevarnost pojava hude hipotenzije in motnje v ledvičnem delovanju.
Rare cases of allergic skin reactions (rash, urticaria), as well as localised swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.
Pri bolnikih, ki so jemali irbesartan so poročali o redkih primerih alergijskih kožnih reakcij (izpuščaj, koprivnica) in o lokaliziranih oteklinah obraza, ustnic in/ali jezika.
Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in some experimental models, the extensive human experience with hydrochlorothiazide has failed to show an association between its use and an increase in neoplasms.
Hidroklorotiazid: na nekaj eksperimentalnih modelih so opazili genotoksično in karcinogeno delovanje hidroklorotiazida, vendar pa dokazi niso zanesljivi.
There is no experience regarding the administration of Irbesartan Hydrochlorothiazide BMS in patients with a recent kidney transplantation.
Izkušenj z uporabo zdravila Irbesartan Hydrochlorothiazide BMS pri bolnikih po nedavni presaditvi ledvice ni.
Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Nesteroidna protivnetna zdravila: pri nekaterih bolnikih se lahko med hkratnim jemanjem nesteroidnih protivnetnih zdravil zmanjša diuretski, natriuretski in antihipertenzijski učinek tiazidnih diuretikov.
The PSUR cycle of Irbesartan Hydrochlorothiazide BMS is aligned with the cross-referred product, KARVEZIDE, until otherwise specified.
Cikel predajanja periodičnih poročil o varnosti zdravila Irbesartan Hydrochlorothiazide BMS, je vezan na referenčno zdravilo KARVEZIDE, dokler ni določeno drugače.
Preparations containing lithium should not be taken with Irbesartan Hydrochlorothiazide BMS without close supervision by your doctor.
Zdravila, ki vsebujejo litij, smete z zdravilom Irbesartan Hydrochlorothiazide BMS jemati le pod strogim zdravniških nadzorom.
There is no clinical experience with Irbesartan Hydrochlorothiazide BMS in patients with hepatic impairment.
Kliničnih izkušenj z uporabo zdravila Irbesartan Hydrochlorothiazide BMS pri bolnikih z jetrno okvaro ni.
Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Jetrna okvara: pri bolnikih z blago do zmerno cirozo farmakokinetični parametri irbesartana niso bistveno spremenjeni.
Your doctor will instruct you how to switch from the previous treatment to Irbesartan Hydrochlorothiazide BMS.
Povedal vam bo tudi, kako prenehati jemati dosedanje zdravilo in kako začeti zdravljenje z zdravilom Irbesartan Hydrochlorothiazide BMS.
Paediatric patients: Irbesartan Hydrochlorothiazide BMS is not recommended for use in children and adolescents due to a lack of data on safety and efficacy.
Otroci in mladostniki: zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba zdravila Irbesartan Hydrochlorothiazide BMS pri otrocih in mladostnikih ni priporočljiva.
Hepatic impairment: Irbesartan Hydrochlorothiazide BMS is not indicated in patients with severe hepatic impairment.
Jetrna okvara: zdravilo Irbesartan Hydrochlorothiazide BMS ni primerno za bolnike s hudo jetrno okvaro.